PS121 - Clarity: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Lopixibat Chloride (Formerly Lum001), a Novel Apical Sodium-Dependent Bile Acid Transporter Inhibitor, in the Treatment of Primary Biliary Cirrhosis Associated with Itching

Journal article

Peer reviewed

M.J Mayo, P Pockros, D Jones, C Bowlus, C Levy, I Patanwala, B Bacon, V Luketic, R Vuppalanchi, S Medendorp, …

Journal of hepatology, Vol.64(2), pp.S197-S197

2016

Metrics

8 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Industry collaboration; Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.151 Pancreas & Gall Bladder Disorders; 1.151.760 Bile Acids
Web Of Science research areas: Gastroenterology & Hepatology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: PS121 - Clarity: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Lopixibat Chloride (Formerly Lum001), a Novel Apical Sodium-Dependent Bile Acid Transporter Inhibitor, in the Treatment of Primary Biliary Cirrhosis Associated with Itching
Creators: M.J Mayo
P Pockros
D Jones
C Bowlus
C Levy
I Patanwala
B Bacon
V Luketic
R Vuppalanchi
S Medendorp
A Dorenbaum
C Kennedy
P Novak
A Raychaudhuri
S Goyal
W Abi-Saab
G.M Hirschfield
Publication Details: Journal of hepatology, Vol.64(2), pp.S197-S197
Publisher: Elsevier B.V
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hepatology
Language: English
Resource Type: Journal article
Record Identifier: 991031714084102976